ATE549624T1 - Verfahren und zusammensetzungen zur diagnose und behandlung von grippe - Google Patents

Verfahren und zusammensetzungen zur diagnose und behandlung von grippe

Info

Publication number
ATE549624T1
ATE549624T1 AT06786341T AT06786341T ATE549624T1 AT E549624 T1 ATE549624 T1 AT E549624T1 AT 06786341 T AT06786341 T AT 06786341T AT 06786341 T AT06786341 T AT 06786341T AT E549624 T1 ATE549624 T1 AT E549624T1
Authority
AT
Austria
Prior art keywords
pdz
methods
compositions
influenza
influenza virus
Prior art date
Application number
AT06786341T
Other languages
English (en)
Inventor
Peter S Lu
Joshua D Rabinowitz
Michael P Belmares
Original Assignee
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp filed Critical Arbor Vita Corp
Application granted granted Critical
Publication of ATE549624T1 publication Critical patent/ATE549624T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06786341T 2005-07-01 2006-07-03 Verfahren und zusammensetzungen zur diagnose und behandlung von grippe ATE549624T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69622105P 2005-07-01 2005-07-01
US72637705P 2005-10-13 2005-10-13
US76529206P 2006-02-02 2006-02-02
US79227406P 2006-04-14 2006-04-14
PCT/US2006/026155 WO2007018843A2 (en) 2005-07-01 2006-07-03 Methods and compositions for diagnosis and treatment of influenza

Publications (1)

Publication Number Publication Date
ATE549624T1 true ATE549624T1 (de) 2012-03-15

Family

ID=37307088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06786341T ATE549624T1 (de) 2005-07-01 2006-07-03 Verfahren und zusammensetzungen zur diagnose und behandlung von grippe

Country Status (8)

Country Link
US (2) US7595151B2 (de)
EP (1) EP1910837B1 (de)
JP (1) JP2009500611A (de)
AT (1) ATE549624T1 (de)
AU (1) AU2006276813A1 (de)
CA (1) CA2613482A1 (de)
IL (1) IL188460A (de)
WO (1) WO2007018843A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1910837B1 (de) * 2005-07-01 2012-03-14 Arbor Vita Corporation Verfahren und zusammensetzungen zur diagnose und behandlung von grippe
US7595152B2 (en) * 2005-07-01 2009-09-29 Arbor Vita Corporation Detection of influenza virus
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
EP2215450B1 (de) * 2006-02-21 2013-07-31 Nexus DX, Inc. Verfahren und zusammensetzungen zum analytnachweis
JP2010507780A (ja) * 2006-10-21 2010-03-11 アーバー ビータ コーポレイション Ｂ型インフルエンザウイルスの検出
RU2337703C1 (ru) * 2007-03-06 2008-11-10 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Средство профилактики и лечения вирусных заболеваний и способ профилактики и лечения вирусных заболеваний
MX344253B (es) * 2007-07-17 2016-12-09 Somalogic Inc Metodo para generar aptameros con constantes de disociacion mejoradas.
WO2009015384A1 (en) * 2007-07-26 2009-01-29 University Of Rochester Nucleic acid binding compounds and methods of use
US8163474B2 (en) * 2008-03-15 2012-04-24 Arbor Vita Corporation NS1-NP diagnostics of influenza virus infection
CN101649356B (zh) * 2009-07-24 2012-09-05 浙江省疾病预防控制中心 甲型h1n1流感病毒荧光定量检测试剂盒及检测方法
KR101341640B1 (ko) * 2010-02-05 2013-12-16 한국전자통신연구원 단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
WO2011146825A2 (en) * 2010-05-20 2011-11-24 The Board Of Trustees Of The University Of Arkansas Avian influenza h5n1 specific aptamers and their use
JP6061932B2 (ja) * 2011-08-12 2017-01-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ピルビン酸デヒドロゲナーゼキナーゼを特異的にレギュレートするための組成物および方法
WO2013073979A1 (en) 2011-11-18 2013-05-23 Thelial Technologies S.A. Method for identifying cancer drug candidates in drosophila
WO2013106909A1 (en) 2012-01-18 2013-07-25 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
KR101471245B1 (ko) * 2012-05-31 2014-12-10 충북대학교 산학협력단 Ａ형 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물
US9493542B2 (en) * 2013-02-22 2016-11-15 Augusta University Research Institute, Inc. Methods of using ERBB2 conjugate peptides
US20140329706A1 (en) * 2013-05-01 2014-11-06 California Institute Of Technology Affinity tags, and related affinity ligands, engineered proteins, modified supports, compositions, methods and systems
JP2018128408A (ja) * 2017-02-10 2018-08-16 東ソー株式会社 抗体凝集体形成予測方法
EP3983804B1 (de) * 2019-06-13 2025-08-06 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Reagenzien und schnelle verfahren zur pathogencharakterisierung und serologieuntersuchung
US11549114B2 (en) * 2020-03-27 2023-01-10 Apollo Biomedical, LLC Multiple rapid detection kits and methods for various viruses
US20210291165A1 (en) * 2020-03-17 2021-09-23 Detect, Inc. Rapid diagnostic test
CN111410694B (zh) * 2020-03-27 2020-12-22 浙江省人民医院 一种抗胶质瘤的多肽分子及其应用
WO2022018622A1 (en) * 2020-07-20 2022-01-27 United Arab Emirates University Method and system for virus and protein-antibody interactions detection and monitoring based on optical light intensity and electrical parameters

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
AU620330B2 (en) 1987-05-29 1992-02-20 Smithkline Beckman Corporation Immunodiagnostic assays using chimeric antigens
DE68928853T2 (de) 1988-05-20 1999-08-05 Cetus Corp., Emeryville, Calif. Befestigung von sequenzspezifischen proben
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
CA2084307A1 (en) 1990-06-01 1991-12-02 Cetus Oncology Corporation Compositions and methods for identifying biologically active molecules
US5846710A (en) 1990-11-02 1998-12-08 St. Louis University Method for the detection of genetic diseases and gene sequence variations by single nucleotide primer extension
US5888819A (en) 1991-03-05 1999-03-30 Molecular Tool, Inc. Method for determining nucleotide identity through primer extension
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
GB9502489D0 (en) 1995-02-09 1995-03-29 Animal Health Trust Expression of the non-structural protein NS1 of influenza virus and detection of anti-NS1 antibody in serum
WO2002007751A1 (en) * 2000-07-25 2002-01-31 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
US7312041B2 (en) * 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
JP4426122B2 (ja) * 2001-01-23 2010-03-03 株式会社ビーエル 血中抗原検出方法及び装置
AU2003270548B2 (en) * 2002-09-09 2008-09-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
JP2004161685A (ja) * 2002-11-14 2004-06-10 Bl:Kk 卵黄関連蛋白およびその用途
JP2004166564A (ja) * 2002-11-19 2004-06-17 Bl:Kk モノクローナル抗体および結核症診断法
JP4933258B2 (ja) * 2003-09-22 2012-05-16 クイデル コーポレーション 試料中の複数分析物の検出装置
JP2006067979A (ja) 2004-09-06 2006-03-16 Bl:Kk インフルエンザａ型ウイルスの免疫検出法
EP1910837B1 (de) * 2005-07-01 2012-03-14 Arbor Vita Corporation Verfahren und zusammensetzungen zur diagnose und behandlung von grippe
US7595152B2 (en) * 2005-07-01 2009-09-29 Arbor Vita Corporation Detection of influenza virus
US7946135B2 (en) * 2007-01-02 2011-05-24 Draka Comteq, B.V. Extended-baking process for glass deposition tubes

Also Published As

Publication number Publication date
EP1910837B1 (de) 2012-03-14
US20070161078A1 (en) 2007-07-12
IL188460A (en) 2012-02-29
CA2613482A1 (en) 2007-02-15
EP1910837A2 (de) 2008-04-16
WO2007018843A3 (en) 2007-06-28
WO2007018843A2 (en) 2007-02-15
US7595151B2 (en) 2009-09-29
HK1115192A1 (en) 2008-11-21
US20100112547A1 (en) 2010-05-06
IL188460A0 (en) 2008-04-13
AU2006276813A1 (en) 2007-02-15
JP2009500611A (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
ATE549624T1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von grippe
WO2007098184A3 (en) Methods and compositions for analyte detection
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
DK2132339T3 (da) Fremgangsmåde til detektering af en analyt i en biologisk matrix
ATE538386T1 (de) Nachweis von krebs anhand von erhöhten bcl-2- konzentrationen
EA201390638A1 (ru) Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения
WO2012035296A3 (en) Assay for prions
DE50113548D1 (de) Verfahren zum Nachweis von Influenza A/B-Viren in Speichel
ATE556030T1 (de) Ultrasensitiver nachweis von analyten
MX340547B (es) Equipos de prueba de diagnostico.
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
WO2007056250A3 (en) Heterogeneous assay of analytes in solution using polymers
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
ATE546550T1 (de) Verfahren zum nachweis von hpv sowie sonden, primer und kits
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
WO2007005948A3 (en) Methods and compositions for diagnosis and treatment of viral and bacterial infections
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
DE502006002073D1 (de) Verfahren zur verhinderung der zeitabhängigen rna-expression in biologischen zellen
RU2007130566A (ru) Способ изготовления контрольного образца для дефектоскопии трубопроводов
ATE432469T1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
ATE444491T1 (de) Verfahren zur bestimmung von kardiovaskulären risikofaktoren
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
BRPI0417231A (pt) método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente